Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Myeloid, Acute 188Leukemia, Lymphocytic, Chronic, B-Cell 69Myelodysplastic Syndromes 47Recurrence 30Leukemia 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Lymphoma, Mantle-Cell 20Leukemia, Myelomonocytic, Chronic 19Hematologic Neoplasms 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Non-Hodgkin 13Lymphoma 13Leukemia, Biphenotypic, Acute 13Burkitt Lymphoma 13Lymphoma, B-Cell, Marginal Zone 12Multiple Myeloma 11Lymphoma, Large B-Cell, Diffuse 11Neoplasms 10Waldenstrom Macroglobulinemia 8Myeloproliferative Disorders 8Lymphoma, Follicular 8Lymphoma, B-Cell 7Neoplasm, Residual 6Leukemia, Myeloid 5Blastic Plasmacytoid Dendritic Cell Neoplasm 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4GATA2 Deficiency 4Leukemia, Monocytic, Acute 3Immunoglobulin Light-chain Amyloidosis 3

Interventions

Cyclophosphamide 8Rituximab 5fludarabine 4Vincristine 4Prednisone 4Doxorubicin 4fludarabine phosphate 3Tacrolimus 3Mycophenolic Acid 3Etoposide 3Busulfan 3venetoclax 2entrectinib 2atezolizumab 2alectinib 2acalabrutinib 2Whole-Body Irradiation 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mesna 2Melphalan 2Bortezomib 2trametinib 1pertuzumab 1pembrolizumab 1obinutuzumab 1liposomal doxorubicin 1isatuximab 1ibrutinib 1etoposide phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoproliferative Disorders × venetoclax × 1 year × Clear all
NCT03467867 2026-04-06

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

Georgetown University

Phase 2 Active not recruiting
25 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoproliferative Disorders, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02966756 2025-12-24

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

AbbVie

Phase 2 Recruiting
110 enrolled
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡